22
Gynecologic Cancer InterGroup Cervix Cancer Research Network Role of Surgery in Cervical Cancer David Cantú MD PhD Cervix Cancer Education Symposium, January 2017, Mexico

Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Role of Surgery in Cervical Cancer

David Cantú MD PhD

Cervix Cancer Education Symposium, January 2017, Mexico

Page 2: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Is it still an Issue to

be explored?

?

Page 3: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)
Page 4: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Continues to be the cornerstone of

treatment in early stages

Page 5: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 6: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Tumor Size

• Desire for fertility preservation

• Neoadjuvant chemotherapy

• Sentinel lymph node

Page 7: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 8: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Minimally Invasive Procedures

Page 9: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 10: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Facilities

• Training

• Preferences

• COSTS!!!!

Page 11: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Locally Advanced Disease

Page 12: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 13: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 14: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 15: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 16: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Recurrent Disease

Page 17: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Objetivo :

Definir selección de px para EP en CaCu recurrente , El grado óptimo de la cirugía en términos de morbilidad y mortalidad.

European Journal of Surgical Oncology (2015), doi: 10.1016/j.ejso.2015.03.235.

Material y Metodos:

•Revisión de la literatura,

•Artículos publicados en los últimos 25 años:

•Exenteración pélvica,

•Cáncer cervical recurrente,

•Tratamiento del cáncer cervical,

•Radioterapia y cáncer de cuello uterino.

Page 18: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

European Journal of Surgical Oncology (2015), doi: 10.1016/j.ejso.2015.03.235.

• .

Descartar la presencia de mets.

• Resección completa del tumor con márgenes quirúrgicos no involucrados y es un fuerte factor pronóstico de supervivencia postoperatoria.

La cirugía curativa requiere

• 40% de EP fueron abortados IOp debido a una enfermedad no resecable.

1989

CaCU recurrente a Distancia:

Para-aórtica 81%

Supraclavicular 7%

Ganglios linfáticos pulmonares 21%

Page 19: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

• Difícil comparar los resultados, – Heterogeneidad respecto al tipo de procedimiento y

el tipo de cáncer que se está investigando (cervical, endometrial, de ovario o vulvar).

• Rara vez se centran únicamente en CaCU y aún más raramente en la recidiva.

• No explican cómo o por qué se eligió un procedimiento dado.

• Márgenes quirúrgicos negativos es un importante factor pronóstico, potencialmente modificable.

European Journal of Surgical Oncology (2015), doi: 10.1016/j.ejso.2015.03.235.

Page 20: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

AutorR Complicacione

s tempranas

Tipo Complicacione

s tardías

tipo Muertes

Berek NR NR NR 17 fitula gatrointetinal 3 (4%)

Goldberg NR NR NR NR 1 (0.9%)

Maggioni 48 (44.8%) NR 52 (48,5%) NR 0

Benn 27 (50%) 10 cardioresp, 6 ileo, 1

obstruction ureteral

33 (61%) 15 ileo, 11 ureteral, 15

hernias

0

McLean NR 15 infections, 8 abscesses, 6

sepsis

NR NR 1 (2%)

Vergote 21 (58%) 2 pelvic abscesses, 14

leaking stomas and

sepsis

18 (50%) 5 pielonefritis

14 fistulas

1 (2%)

Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic

infections

48 (44.8%) 8 fistulas, 9 occlusions, 16

Obstruction urinaria

13 (12%)

Yoo 10 (16 %) 4 skin infections, 1 ileus

5 fistulas, 3 wound

dehiscences

22 (36%) 10 fistulas (7

enterocutaneea,

2 rectovaginal, 1

Ureteroenteric)

0

Schmidt 143 (51%) 42 rectovaginal fistulas, 20

pelvic

abscesses, 10 pulmonary

emboli

NR NR 14 (5%)

Tanaka 10 ( 83%) 5 ileus, 3 leaking

gastrointenstinal

anastomoses

NR NR 0

Chiantera 48 8 21.3%) 23 sepsis, 15

cardiorespiratory, 39 wound

dehiscences, 22 urinary, 29

gastrointenstinal

NR NR 7 (3%)

European Journal of Surgical Oncology (2015), doi: 10.1016/j.ejso.2015.03.235.

Page 21: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Palliative Procedures

– Ileal Conduit

– Colostomy

– Other diversions

– Other Procedures

Page 22: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Is it still an Issue to

be explored?

?